Back to search results

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

IsraelRecruitingPHASE2, PHASE3

Conditions

Non-Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Moores Cancer Center /ID# 267782, La Jolla, California, United States

  • Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States

  • Bond Clinic /ID# 262611, Winter Haven, Florida, United States

    Study coordinator · 863-293-1191 ex 3790

  • University Cancer & Blood Cent /ID# 261824, Athens, Georgia, United States

  • The University of Chicago Medical Center /ID# 262259, Chicago, Illinois, United States

  • University of Kansas Medical Center /ID# 263196, Westwood, Kansas, United States

  • Baptist Health Lexington /ID# 261823, Lexington, Kentucky, United States

  • Cancer & Hematology Centers of Western Michigan - East /ID# 261826, Grand Rapids, Michigan, United States

    Study coordinator · 616-975-3065

  • Washington University-School of Medicine /ID# 262759, St Louis, Missouri, United States

  • Stony Brook Cancer Center /ID# 261954, Stony Brook, New York, United States

  • Cone Health Cancer Center /ID# 262583, Greensboro, North Carolina, United States

  • Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati, Ohio, United States

  • Guthrie Robert Packer Hospital /ID# 262758, Sayre, Pennsylvania, United States

  • Renovatio clinical /ID# 262000, El Paso, Texas, United States

  • Houston Methodist Hospital /ID# 262722, Houston, Texas, United States

  • Texas Oncology - Plano East /ID# 264356, Plano, Texas, United States

  • Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311, San Antonio, Texas, United States

  • Renovatio Clinical /ID# 261999, The Woodlands, Texas, United States

  • Vista Oncology - East Olympia /ID# 262303, Olympia, Washington, United States

  • Canberra Hospital /ID# 261891, Garran, Australian Capital Territory, Australia

  • Nepean Hospital /ID# 262157, Kingswood, New South Wales, Australia

  • Westmead Hospital /ID# 261894, Westmead, New South Wales, Australia

  • Universitair Ziekenhuis Antwerpen /ID# 261270, Edegem, Antwerpen, Belgium

  • Cliniques Universitaires UCL Saint-Luc /ID# 261267, Brussels, Brussels Capital, Belgium

  • Hospital La Louviere Site Jolimont - Helora /ID# 261269, La Louvière, Hainaut, Belgium

  • Groupe Sante CHC - Clinique du MontLegia /ID# 262338, Liège, Liege, Belgium

  • AZ Maria Middelares /ID# 262313, Ghent, Belgium

  • UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 262557, Namur, Belgium

  • Centro de Investigacion y Desarrollo Oncologico /ID# 261800, Temuco, Araucania, Chile

  • Oncored /Id# 261801, Vitacura, Region Metropolitana Santiago, Chile

  • Fundacion Arturo Lopez Perez /ID# 261700, Providencia, Santiago Metropolitan, Chile

  • Sociedad Cem-Cancer Spa /Id# 262316, Viña del Mar, Valparaiso, Chile

  • Hospital Clinico Universidad De Los Andes /ID# 262665, Santiago, Chile

  • APHM - Hopital Nord /ID# 261129, Marseille, Bouches-du-Rhone, France

  • CHU Grenoble - Hopital Michallon /ID# 261131, La Tronche, Isere, France

  • Institut Curie /ID# 261127, Paris, Paris, France

  • Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 261644, Bron, Rhone, France

  • Centre Hosp Intercommunal de Creteil /ID# 261130, Créteil, Val-de-Marne, France

  • Shaare Zedek Medical Center /ID# 262432, Jerusalem, Jerusalem, Israel

  • Rambam Health Care Campus /ID# 262431, Haifa, Israel

  • National Cancer Center Hospital East /ID# 261923, Kashiwa-shi, Chiba, Japan

  • Saitama Prefectural Cancer Center /ID# 262703, Kitaadachi-gun, Saitama, Japan

  • National Cancer Center Hospital /ID# 261925, Chuo-ku, Tokyo, Japan

  • Ziekenhuis St. Jansdal /ID# 261193, Harderwijk, Gelderland, Netherlands

  • Zuyderland Medisch Centrum /ID# 261190, Heerlen, Limburg, Netherlands

  • Isala /ID# 262458, Zwolle, Overijssel, Netherlands

  • Pan American Center for Oncology Trials /ID# 269666, Rio Piedras, Puerto Rico

  • Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 262723, Santiago de Compostela, A Coruna, Spain

  • Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 262118, L'Hospitalet de Llobregat, Barcelona, Spain

  • UOMi Cancer Center - Clinica Tres Torres /ID# 262116, Barcelona, Spain

  • Hospital Universitario Vall de Hebron /ID# 262113, Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 262114, Madrid, Spain

  • Hospital Universitario 12 de Octubre /ID# 262112, Madrid, Spain

  • Hospital Clinico Universitario de Valencia /ID# 262115, Valencia, Spain

  • National Cheng Kung University Hospital /ID# 262016, Tainan, Taiwan

  • Mackay Memorial Hospital /ID# 262534, Taipei, Taiwan

  • Taipei Medical University Hospital /ID# 262020, Taipei, Taiwan

  • Linkou Chang Gung Memorial Hospital /ID# 262535, Taoyuan City, Taiwan

  • Gazi University Medical Faculty /ID# 261786, Ankara, Turkey (Türkiye)

  • Ankara City Hospital /ID# 261785, Ankara, Turkey (Türkiye)

  • Dr. Suat Seren Gogus Has /ID# 261789, Izmir, Turkey (Türkiye)

Study leads

  • ABBVIE INC.

    Study Director

    AbbVie

View source on ClinicalTrials.gov(opens in a new tab)